查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1978847

Sunitinib酸盐市场：按适应症、治疗阶段、最终用户和分销管道划分 - 全球预测，2026-2032 年

Sunitinib Malate Market by Indication, Line Of Treatment, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年Sunitinib酸盐市值为 1.4843 亿美元，预计到 2026 年将成长至 1.6695 亿美元，复合年增长率为 11.69%，到 2032 年将达到 3.2201 亿美元。

主要市场统计数据
基准年 2025 1.4843亿美元
预计年份：2026年 1.6695亿美元
预测年份：2032年 3.2201亿美元
复合年增长率 (%) 11.69%

本书清晰而权威地介绍了Sunitinib替尼的治疗作用，以及影响肿瘤学临床和商业性决策的策略考量。

Sunitinib酸盐已成为多种肿瘤适应症的基础标标靶治疗。鑑于其近期的临床和商业性进展，有必要对其进行简明扼要的管理概述。本文概述了该化合物的治疗特性，重点阐述其多靶点受体蛋白酪氨酸激酶抑制活性及其在血管生成和致癌性信号通路是疾病进展主要驱动因素的疾病中的临床意义。以下分析将舒尼替尼置于不断发展的治疗范式、监管对话和相关人员期望的背景下，并着重于Sunitinib证据与商业策略之间的相互作用。

精准诊断、口服抗癌药物治疗模式的进步以及不断变化的支付方环境，是如何重新定义临床定位和商业策略的？

标靶癌症治疗领域正经历变革性的转变，其影响范围不仅限于新型分子药物的引入，还涵盖了诊断、医疗服务和支付方趋势。精准肿瘤学不断改变治疗选择的方向，更精细的基因组和表型特征分析使得Sunitinib等药物能够针对不同的肿瘤亚型进行差异化应用。随着生物标记的进步，口服抗癌药物的兴起正在改变患者管理的模式，门诊管道、用药依从性策略和远端监测技术的重要性日益凸显。

评估美国关税措施对供应链韧性、采购和市场进入。

对源自美国或经美国转运的药品原料和成品征收关税，将对全球供应链和商业营运产生实际影响。当关税影响活性成分、成品製剂或原料时，製造商可能面临生产成本增加，而这些影响会影响采购、生产週期和库存策略。因此，在合约和监管限制价格柔软性的市场中，销售部门必须重新评估其定价策略、与分销商的谈判以及商店的价格定位。

详细的细分揭示了适应症、治疗方案、医疗机构和分销管道如何影响临床应用案例和商业性重点。

一套精细的细分框架揭示了Sunitinib在不同临床环境和商业管道中的使用和价值提案的差异。在适应症层面进行区分，可以清楚地识别生物学亚组和治疗目标。胃肠道基质肿瘤（GIST）包括KIT突变型、PDGFRα突变型和野生型肿瘤，它们对激酶抑制剂的反应各不相同。同时，胰臟神经内分泌肿瘤（PNET）分为功能性和非功能性两种状态，其症状负担和治疗目标也存在差异；肾细胞癌则分为透明细胞癌和非透明细胞癌两种组织学类型，其预后和治疗方案也存在差异。这种适应症层面的分层会影响临床决策、临床实验室设计以及伴随诊断策略的发展。

区域监管差异、支付方模式和分销基础设施如何推动美洲、欧洲、中东、非洲和亚太地区采取差异化的准入策略？

区域趋势正对全球监管管道、报销标准和相关人员的期望产生重大影响。在美洲，监管机构和支付方关注的是相对临床获益和成本效益，而医疗保健系统则涵盖了从高度集中的采购机製到分散的私人支付方网络，这影响着新技术的采用速度和合约的复杂性。一些市场朝向以金额为准的合约模式的转变，促使製药公司在传统的实证方案之外，也开始提供与疗效挂钩的提案。

靶向肿瘤学领域中塑造治疗差异化、生命週期策略和合作机会的竞争定位和策略行动

Sunitinib领域的竞争格局呈现出成熟产品与新疗法并存的局面，二者都对临床定位与策略重点产生影响。成熟的製药公司持续管理长期临床安全性和有效性数据，而新药则透过拓展适应症、提高耐受性或基于生物标记的疗效声明来凸显自身优势。此外，各公司也在强化自身的价值提案，并投资于真实世界数据（REW）的收集和核准后研究，以支持与支付者和医疗系统的谈判。

为了确保可持续地获得治疗和竞争优势，我们需要一个切实可行的跨部门策略，将证据产生、市场进入和供应韧性整合起来。

行业领导企业应优先考虑整合临床开发、市场进入和供应链韧性的整合策略，以确保患者用药可及性和商业性永续性。这首先需要对每项适应症的临床价值和真实世界疗效进行严格评估，并辅以针对性证据，直接回应支付方的关切和治疗特定亚组患者的临床医生的需求。同时，商业部门应针对第一线治疗和后续治疗建构差异化的宣传策略，并根据医院和专科诊所的采购和製剂习惯，优化其针对不同机构的推广方式。

我们高度透明和系统化的研究途径，结合文献综述、专家访谈和质性检验，得出切实可行的见解。

本报告的研究结合了系统性的文献整合、专家访谈和质性分析，建构了可靠的证据基础。研究人员对同行评审的临床文献、监管文件和治疗指南进行了深入审查，以阐明相关化合物的临床背景、作用机制和适应症演变。此外，研究人员还与临床医生、医保专家和供应链专家进行了结构化访谈，从而获得了关于药物使用模式、支付方关注点和营运挑战的最新见解。

简洁的整合强调了整合证据、获取策略和营运准备的必要性，以确保持续的治疗意义。

总之，在不断发展的肿瘤治疗领域，Sunitinib酸盐仍然是一种具有临床意义的选择，而适应性强的商业和运作策略至关重要。复杂的诊断技术、不断涌现的竞争疗法以及支付方的严格审查，都要求製造商和合作伙伴认真考虑证据产生、相关人员参与以及供应链风险管理。针对不同适应症的生物学特性、治疗方案预期以及医院和专科诊所的具体情况制定细分策略，对于维持其在不同市场的相关性和可近性至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：苹果酸Sunitinib尼市场：依适应症划分

  • 胃肠道基质肿瘤
    • KIT变体
    • PDGRA 变体
    • 野生型
  • 胰臟神经内分泌肿瘤
    • 功能
    • 不具备功能
  • 肾臟细胞癌
    • 透明细胞癌
    • 非透明细胞癌

第九章：Sunitinib酸盐市场：依治疗阶段划分

  • 一线治疗
  • 二线治疗
  • 三线治疗

第十章：苹果酸Sunitinib尼市场：依最终用户划分

  • 医院
  • 专科诊所

第十一章：苹果酸Sunitinib尼市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：苹果酸Sunitinib尼市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：苹果酸Sunitinib尼市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：苹果酸Sunitinib尼市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国舒尼替Sunitinib酸盐市场

第十六章：中国Sunitinib酸盐市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aark Pharmaceuticals
  • Active BIoTech AB
  • Anant Pharmaceuticals Pvt. Ltd.
  • AstraZeneca PLC
  • Beijing Lunarsun Pharmaceutical Co., Ltd.
  • Bio-Techne Corporation
  • Brawn Laboratories Ltd.
  • Hetero Labs Limited
  • Hikma Pharmaceuticals PLC
  • JEIL PHARMACEUTICAL CO.,LTD.
  • Manus Aktteva Biopharma LLP
  • Medichem SA
  • Medzeel Lifescience
  • Nanjing First Pharmaceutical Co. Ltd
  • Natco Pharma Limited
  • Pfizer Inc.
  • Sichuan Xieli Pharmaceutical Co., Ltd.
  • Synthland Limited
  • Taj Pharma India Limited
  • TargetMol Chemicals Inc.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-2A0283E25693

The Sunitinib Malate Market was valued at USD 148.43 million in 2025 and is projected to grow to USD 166.95 million in 2026, with a CAGR of 11.69%, reaching USD 322.01 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 148.43 million
Estimated Year [2026] USD 166.95 million
Forecast Year [2032] USD 322.01 million
CAGR (%) 11.69%

Clear and authoritative framing of sunitinib malate's therapeutic role and strategic considerations shaping clinical and commercial decisions in oncology

Sunitinib malate has established itself as a cornerstone targeted therapy across several oncologic indications, and recent clinical and commercial developments warrant a concise executive-level synthesis. This introduction frames the therapeutic profile of the compound, highlighting its multitargeted receptor tyrosine kinase inhibition and its clinical relevance in disorders where angiogenesis and oncogenic signaling are primary drivers of disease progression. The following analysis situates sunitinib within evolving treatment paradigms, regulatory dialogues, and stakeholder expectations while emphasizing the interplay between clinical evidence and commercial strategy.

Beyond mechanism of action, contextual factors shape product trajectories: evolving biomarker characterization, emergent competitor agents, and shifts in care delivery all influence how sunitinib is utilized across patient populations. The introduction outlines the scope of the subsequent sections, which cover transformational market shifts, policy impacts, granular segmentation insights, regional dynamics, competitor behavior, recommended actions, and the methodological approach underpinning the research. Together, these elements provide a cohesive vantage point for leaders evaluating therapeutic positioning, lifecycle management, and portfolio prioritization in oncology.

How converging advances in precision diagnostics, oral oncology care models, and payer evolution are redefining clinical positioning and commercial strategies

The landscape for targeted oncology therapies is undergoing transformative shifts that extend beyond new molecule introductions to encompass diagnostics, care delivery, and payer dynamics. Precision oncology continues to reorient treatment selection, with more granular genomic and phenotypic characterization driving differential utilization of agents like sunitinib across tumor subtypes. Parallel to biomarker advances, the rise of oral oncolytics has changed patient management paradigms, increasing the relevance of outpatient care pathways, medication adherence strategies, and remote monitoring technologies.

In addition, evolving competitive pressures-ranging from next-generation kinase inhibitors to combination regimens involving immune-oncology agents-are prompting reassessments of sunitinib's role in therapy sequences. Regulatory pathways and label amendments driven by new evidence can rapidly alter clinical positioning, and payers are responding with tighter utilization management and value-based contracting experiments. From a commercial perspective, these forces necessitate more sophisticated stakeholder engagement, adaptive market access strategies, and investment in real-world evidence to substantiate comparative effectiveness. Consequently, organizations must integrate clinical, regulatory, and payer intelligence to sustain therapeutic relevance and patient access.

Assessing the operational and commercial implications of United States tariff actions on supply chains, procurement, and market access resilience

The imposition of tariffs on pharmaceutical inputs and finished products originating from or transiting through the United States has practical implications for global supply chains and commercial operations. Where tariffs affect active pharmaceutical ingredients, finished formulations, or raw materials, manufacturers may confront increased production costs that ripple through procurement, manufacturing cadence, and inventory policies. In turn, commercial teams must reassess pricing strategies, contract negotiations with distributors, and shelf-price positioning in markets where contractual and regulatory constraints limit price flexibility.

Operational responses often include sourcing diversification, nearshoring of manufacturing, and renegotiation of supplier terms to mitigate exposure. These adjustments can introduce lead-time variability and transitional quality oversight requirements, necessitating strengthened supplier qualification processes. Health systems and specialty clinics may absorb cost increases differently than hospitals, which can affect the relative economics of distribution channels and formulary placements. Moreover, tariffs interact with regulatory frameworks and reimbursement rules, potentially complicating market access discussions.

Strategically, stakeholders should evaluate the tariff environment as a material factor in procurement risk assessments and contingency planning. Cross-functional teams combining procurement, regulatory affairs, and market access should model scenario pathways and identify mitigations that preserve both supply continuity and patient access without compromising quality or compliance.

In-depth segmentation revealing how indications, treatment lines, care settings, and distribution routes shape clinical use cases and commercial priorities

A nuanced segmentation framework illuminates how sunitinib's use and value proposition vary across clinical settings and commercial channels. Indication-level differentiation captures distinct biological subgroups and therapeutic intents: Gastrointestinal Stromal Tumor encompasses Kit mutant, PDGFRA mutant, and wild-type variants that respond differently to kinase inhibition, while Pancreatic Neuroendocrine Tumor divides into functional and nonfunctional presentations with divergent symptom burdens and treatment goals, and Renal Cell Carcinoma separates into clear cell and non-clear cell histologies with distinct prognostic and therapeutic profiles. These intra-indication strata influence clinical decision-making, trial design, and the design of companion diagnostic strategies.

Line-of-treatment segmentation reveals how first-line, second-line, and third-line settings demand different value narratives; early-line use emphasizes comparative efficacy and tolerability, whereas later-line positioning often relies on demonstrated benefit in refractory populations and manageable safety profiles. End-user segmentation differentiates settings of care-hospitals versus specialty clinics-each with unique procurement processes, prescribing behaviors, and patient support needs that shape access pathways. Finally, distribution channel distinction among hospital pharmacies, online pharmacies, and retail pharmacies has implications for adherence programs, reimbursement touchpoints, and the logistics of oral oncolytic delivery. Integrating these segmentation lenses supports targeted clinical development, commercial planning, and market access execution.

How regional regulatory diversity, payer models, and distribution infrastructure drive differentiated access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exert a pronounced influence on regulatory pathways, reimbursement norms, and stakeholder expectations across the globe. In the Americas, regulatory authorities and payers emphasize comparative clinical benefit and cost-effectiveness, while health systems vary from highly centralized procurement mechanisms to decentralized private payer networks, affecting adoption cadence and contracting complexity. Shifts toward value-based arrangements in some markets are prompting manufacturers to present outcomes-linked propositions alongside traditional evidence packages.

Across Europe, Middle East & Africa, heterogeneity in regulatory frameworks and health technology assessment standards creates a mosaic of access timelines and evidence requirements. Pricing negotiations and reimbursement decisions in these regions frequently hinge on external reference pricing and national clinical guidelines, so localized evidence generation and stakeholder engagement remain essential. In Asia-Pacific, accelerated regulatory pathways and expanding clinical trial ecosystems coexist with diverse payer landscapes; some jurisdictions are rapidly adopting innovative access schemes while others maintain conservative reimbursement criteria. Differences in manufacturing capacity, distribution infrastructure, and patient care models across regions necessitate tailored commercialization approaches that account for regulatory alignment, supply logistics, and localized evidence needs.

Competitive positioning and strategic behaviors shaping therapeutic differentiation, lifecycle initiatives, and partnership opportunities in targeted oncology

Competitive dynamics in the sunitinib landscape reflect a mix of legacy incumbency and new therapeutic entrants, each influencing clinical positioning and strategic priorities. Established manufacturers continue to steward long-term clinical safety and efficacy data, while newer agents pursue label extensions, improved tolerability, or biomarker-driven claims to differentiate themselves. Companies are also investing in real-world evidence generation and post-approval studies to reinforce value propositions and to support negotiations with payers and health systems.

Commercial behavior spans lifecycle management tactics such as indication expansion strategies, formation of patient support programs for oral therapy adherence, and partnerships to enhance distribution reach. On the manufacturing front, firms are optimizing capacity and supply resilience to reduce vulnerability to procurement disruptions and tariff-related cost pressures. Strategic collaborations with diagnostic developers and academic consortia are increasingly common, seeking to align therapeutic use with emerging precision oncology paradigms. For stakeholders evaluating partnerships or competitive responses, the emphasis should be on complementary capabilities in clinical evidence generation, market access expertise, and operational agility.

Actionable cross-functional strategies to align evidence generation, market access, and supply resilience for sustained therapeutic access and competitive advantage

Industry leaders should prioritize integrated strategies that align clinical development, market access, and supply chain resilience to preserve patient access and commercial viability. Initiatives should begin with a rigorous assessment of indication-specific clinical value and real-world performance, complemented by targeted evidence generation that speaks directly to payer concerns and to clinicians treating distinct subpopulations. In parallel, commercial teams should develop differentiated narratives for first-line versus later-line use and tailor engagement to hospitals and specialty clinics based on their procurement and prescribing behaviors.

Operationally, leaders must diversify sourcing and strengthen supplier qualification to reduce exposure to tariff and trade disruptions, while also investing in distribution strategies that leverage hospital pharmacies, retail partners, and secure online dispensing models to reach patients safely and efficiently. Collaborative approaches with diagnostic providers can sharpen patient selection and improve the likelihood of favorable reimbursement decisions. Finally, adopting adaptive pricing and contracting mechanisms, including outcomes-based agreements where feasible, will support constructive dialogues with payers and sustain access in value-conscious environments. Acting on these priorities will require cross-functional governance and a commitment to agile execution.

Transparent and methodical research approach combining literature review, expert interviews, and qualitative triangulation to derive actionable insights

The research underpinning this report combines systematic literature synthesis, expert interviews, and qualitative analysis to build a robust evidence base. Peer-reviewed clinical literature, regulatory documents, and treatment guidelines were reviewed to establish the clinical context, mechanism of action, and label histories relevant to the compound. In addition, structured interviews with clinicians, reimbursement experts, and supply chain professionals provided contemporary perspectives on utilization patterns, payer concerns, and operational challenges.

Analytical methods emphasized triangulation across sources to validate key themes and to identify areas of consensus and divergence. The research process involved mapping segmentation lenses-indication subtypes, line-of-treatment contexts, care settings, and distribution channels-to observed behaviors in practice and to emergent commercial tactics. Care was taken to ensure that conclusions reflected qualitative evidence and expert judgment without relying on proprietary datasets. Transparency about assumptions and methodological constraints was maintained, and stakeholders can request methodological appendices or interview summaries to better understand the provenance of specific insights.

Concise synthesis highlighting the imperative for integrated evidence, access strategies, and operational preparedness to secure sustained therapeutic relevance

In conclusion, sunitinib malate remains a clinically meaningful option within a shifting oncology ecosystem that demands adaptive commercial and operational approaches. The interplay of precision diagnostics, evolving therapeutic competitors, and payer scrutiny requires manufacturers and partners to be deliberate about evidence generation, stakeholder engagement, and supply chain risk management. Segment-specific strategies-attuned to indication biology, line-of-treatment expectations, and the nuances of hospitals versus specialty clinics-will be essential to maintain relevance and access across diverse markets.

Furthermore, external forces such as tariff regimes and regional regulatory heterogeneity underscore the need for proactive procurement and market access planning. By aligning clinical strategy with pragmatic operational measures and by fostering collaborative relationships with diagnostic providers and health systems, organizations can better navigate uncertainties and protect patient access. Ultimately, success will hinge on an integrated approach that balances scientific rigor, commercial acumen, and operational resilience.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sunitinib Malate Market, by Indication

  • 8.1. Gastrointestinal Stromal Tumor
    • 8.1.1. Kit Mutant
    • 8.1.2. Pdgra Mutant
    • 8.1.3. Wild Type
  • 8.2. Pancreatic Neuroendocrine Tumor
    • 8.2.1. Functional
    • 8.2.2. Non Functional
  • 8.3. Renal Cell Carcinoma
    • 8.3.1. Clear Cell Carcinoma
    • 8.3.2. Non-Clear Cell Carcinoma

9. Sunitinib Malate Market, by Line Of Treatment

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Sunitinib Malate Market, by End User

  • 10.1. Hospital
  • 10.2. Specialty Clinic

11. Sunitinib Malate Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Sunitinib Malate Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Sunitinib Malate Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Sunitinib Malate Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Sunitinib Malate Market

16. China Sunitinib Malate Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Aark Pharmaceuticals
  • 17.6. Active Biotech AB
  • 17.7. Anant Pharmaceuticals Pvt. Ltd.
  • 17.8. AstraZeneca PLC
  • 17.9. Beijing Lunarsun Pharmaceutical Co., Ltd.
  • 17.10. Bio-Techne Corporation
  • 17.11. Brawn Laboratories Ltd.
  • 17.12. Hetero Labs Limited
  • 17.13. Hikma Pharmaceuticals PLC
  • 17.14. JEIL PHARMACEUTICAL CO.,LTD.
  • 17.15. Manus Aktteva Biopharma LLP
  • 17.16. Medichem S.A.
  • 17.17. Medzeel Lifescience
  • 17.18. Nanjing First Pharmaceutical Co. Ltd,
  • 17.19. Natco Pharma Limited
  • 17.20. Pfizer Inc.
  • 17.21. Sichuan Xieli Pharmaceutical Co., Ltd.
  • 17.22. Synthland Limited
  • 17.23. Taj Pharma India Limited
  • 17.24. TargetMol Chemicals Inc.
  • 17.25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SUNITINIB MALATE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SUNITINIB MALATE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS SUNITINIB MALATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 140. GCC SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 141. GCC SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 142. GCC SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 143. GCC SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GCC SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 164. G7 SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 165. G7 SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 166. G7 SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 167. G7 SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. G7 SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 172. NATO SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 173. NATO SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 174. NATO SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 175. NATO SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NATO SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)